3. Egaten

World Health Organization (WHO)
(World Health Organization)

Active ingredient: triclabendazole
Disease: fascioliasis (liver fluke infection)
Peak sales estimate: n/a
Approved: Feb. 13, 2019
Company: Novartis

The scoop: Although triclabendazole has been used for years to treat parasitic infections in animals, Novartis brought the drug to its first FDA nod. Called Egaten, it is approved to treat liver fluke infection in patients aged 6 and up. The parasite larvae infect humans who consume contaminated food or water, and then mature into adult worms in the liver, gallbladder and bile ducts. The Swiss pharma has been donating Egaten to the World Health Organization since 2005, but it sees U.S. approval as an “important milestone” that will boost access to the treatment. “FDA approval of Egaten is expected to facilitate drug licensing and import to these countries, helping ensure sufficient and prompt availability of the drug when needed,” the company said. Egaten remains the only medicine recommended by the WHO to treat liver fluke infection. — Amirah Al Idrus

3. Egaten

Suggested Articles

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.